As of 2024-12-15, the EV/EBITDA ratio of Neurocrine Biosciences Inc (NBIX) is 20.21. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NBIX's latest enterprise value is 12,479.27 mil USD. NBIX's TTM EBITDA according to its financial statements is 617.50 mil USD. Dividing these 2 quantities gives us the above NBIX EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 15.7x - 16.5x | 15.9x |
| Forward P/E multiples | 15.5x - 26.6x | 17.6x |
| Fair Price | 54.34 - 104.08 | 80.91 |
| Upside | -57.1% - -17.9% | -36.1% |
| Date | EV/EBITDA |
| 2024-12-13 | 20.21 |
| 2024-12-12 | 20.22 |
| 2024-12-11 | 20.46 |
| 2024-12-10 | 20.58 |
| 2024-12-09 | 20.61 |
| 2024-12-06 | 20.45 |
| 2024-12-05 | 20.16 |
| 2024-12-04 | 20.38 |
| 2024-12-03 | 20.00 |
| 2024-12-02 | 20.08 |
| 2024-11-29 | 20.22 |
| 2024-11-27 | 20.19 |
| 2024-11-26 | 20.41 |
| 2024-11-25 | 20.28 |
| 2024-11-22 | 20.04 |
| 2024-11-21 | 19.93 |
| 2024-11-20 | 19.65 |
| 2024-11-19 | 18.97 |
| 2024-11-18 | 18.72 |
| 2024-11-15 | 18.69 |
| 2024-11-14 | 19.58 |
| 2024-11-13 | 20.01 |
| 2024-11-12 | 20.26 |
| 2024-11-11 | 20.29 |
| 2024-11-08 | 20.05 |
| 2024-11-07 | 19.76 |
| 2024-11-06 | 19.98 |
| 2024-11-05 | 19.36 |
| 2024-11-04 | 19.20 |
| 2024-11-01 | 19.47 |
| 2024-10-31 | 19.16 |
| 2024-10-30 | 19.82 |
| 2024-10-29 | 18.49 |
| 2024-10-28 | 18.49 |
| 2024-10-25 | 18.47 |
| 2024-10-24 | 18.38 |
| 2024-10-23 | 18.30 |
| 2024-10-22 | 18.58 |
| 2024-10-21 | 18.55 |
| 2024-10-18 | 18.78 |
| 2024-10-17 | 18.86 |
| 2024-10-16 | 18.84 |
| 2024-10-15 | 18.67 |
| 2024-10-14 | 18.53 |
| 2024-10-11 | 18.37 |
| 2024-10-10 | 17.87 |
| 2024-10-09 | 17.74 |
| 2024-10-08 | 17.74 |
| 2024-10-07 | 17.83 |
| 2024-10-04 | 18.13 |